var data={"title":"Clobetasone (United States: Not available): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Clobetasone (United States: Not available): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/794145?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=clobetasone-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">see &quot;Clobetasone (United States: Not available): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46443940\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Spectro EczemaCare Medicated Cream [OTC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46443942\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Corticosteroid, Topical</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46447011\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Dermatitis:</b> Topical: Apply sparingly to affected area twice daily; after ~7 days assess need for continued therapy. When used OTC do not exceed 15 g/week.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46447012\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Dermatitis:</b> Children &ge;12 years and Adolescents: Topical: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46447013\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. Apply the least amount and for the shortest duration necessary to achieve desired clinical effect.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46447015\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no specific dosage adjustments provided in the manufacturer&rsquo;s labeling. Apply the least amount and for the shortest duration necessary to achieve desired clinical effect.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46447016\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no specific dosage adjustments provided in the manufacturer&rsquo;s labeling. Apply the least amount and for the shortest duration necessary to achieve desired clinical effect.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46443941\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46447021\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cream, External, as butyrate:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Spectro EczemaCare Medicated Cream: 0.05% (30 g)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46447020\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Not available in the US</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46447017\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Topical: Wash hands prior to and after administration. Apply sparingly to affected area with fingertip as directed in product labeling. Do not cover treated area. Avoid contact with eyes.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46446873\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Not approved in the US</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dermatitis:</b> Management of localized eczema and dermatitis including atopic eczema and irritant and allergic contact dermatitis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46731052\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Hypertension</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Exacerbation of eczema, skin atrophy (local changes; with long-term use)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Adrenal suppression (transient; when treating large areas), decreased cortisol, glycosuria, growth suppression (including slow growth and delayed weight gain), increased serum glucose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Local hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Osteoporosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Cataract, increased intraocular pressure</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46447005\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to clobetasone or any component of the formulation; as monotherapy in the treatment of fungal (eg, candidiasis), bacterial (eg, impetigo), or primary cutaneous viral (eg, herpes simplex, vaccinia, varicella) skin infections; acne vulgaris; rosacea; psoriasis; pruritus without rash</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46447006\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Contact dermatitis: Allergic contact dermatitis can occur and is usually diagnosed by failure to heal rather than clinical exacerbation; discontinue use if irritation occurs and treat appropriately.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity reactions may rarely occur; discontinue use if signs/symptoms of hypersensitivity occur and treat as indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunosuppression: Prolonged use may result in fungal or bacterial superinfection; discontinue if dermatological infection persists despite appropriate antimicrobial therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Skin reactions: Discontinue if skin irritation or contact dermatitis occurs; do not use in patients with decreased skin circulation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Systemic effects: Topical corticosteroids may be absorbed percutaneously. Absorption of topical corticosteroids may cause manifestations of Cushing syndrome (rare), hyperglycemia, or glycosuria (B&ouml;ckle 2014; Dhar 2014; Hengge 2006). Absorption is increased by the use of occlusive dressings, application to denuded skin, application to large surface areas, or prolonged use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Because of the risk of adverse effects associated with systemic absorption, topical corticosteroids should be used cautiously in the elderly in the smallest possible effective dose for the shortest duration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Children may absorb proportionally larger amounts after topical application and may be more prone to systemic effects. HPA axis suppression, intracranial hypertension, and Cushing syndrome have been reported in children receiving topical corticosteroids (Halverstam 2007; Hosking 1978). Prolonged use may affect growth velocity; growth should be routinely monitored in pediatric patients (Kristmundsdottir 1987).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: For external use on intact skin only; avoid contact with eyes. Do not apply to the face, scalp, genitals, groin, axilla, or between toes without medical supervision. Do not cover treated area with occlusive dressings. If symptoms fail to improve within a few days to a week, discontinue use and reassess. Not indicated as monotherapy for bacterial, fungal, or viral skin infections; may be used as adjunctive therapy for skin infections with inflammatory component.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46221694\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46221691\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=107874&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Corticosteroids may enhance the hyperglycemic effect of Ceritinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itraconazole: May increase the serum concentration of Clobetasone.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: Corticosteroids may enhance the adverse/toxic effect of Ritodrine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritonavir: May increase the serum concentration of Clobetasone.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46446874\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed with corticosteroids in animal reproduction studies. Topical corticosteroids are preferred over systemic for treating conditions, such as psoriasis or atopic dermatitis in pregnant women. Topical products are not recommended for extensive use, in large quantities, or for long periods of time in pregnant women (Koutroulis 2011; Leachman 2006).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46446886\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Corticosteroids are excreted in human milk. It is not known if systemic absorption following topical administration results in detectable quantities in human milk. Do not apply topical corticosteroids to nipples; hypertension was noted in a nursing infant exposed to a topical corticosteroid while nursing (Leachman 2006).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46447019\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">HPA axis suppression and adrenal insufficiency</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46447009\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Topical corticosteroids have anti-inflammatory, antipruritic, and vasoconstrictive properties. May depress the formation, release, and activity of endogenous chemical mediators of inflammation (kinins, histamine, liposomal enzymes, prostaglandins) through the induction of phospholipase A2 inhibitory proteins (lipocortins) and sequential inhibition of the release of arachidonic acid. Clobetasone has intermediate range potency.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46507009\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Amisel (SG);</li>\n      <li>Becoderm-C (NZ);</li>\n      <li>Becoderm-C Flare-Up Eczema and Dermatitis Cream (AU);</li>\n      <li>Benate (VN);</li>\n      <li>Benate Forte (VN);</li>\n      <li>Clobate (AE, KW, SA);</li>\n      <li>Clobavate (GB);</li>\n      <li>Clobeson (QA, SA);</li>\n      <li>Clobet (IT);</li>\n      <li>Emovat (DK, FI, SE);</li>\n      <li>Emovate (CH, DE, ES, NL, PT);</li>\n      <li>Eumovate (AT, BD, BE, EG, GB, HK, IE, IL, IT, KR, LU, MT, SG, TR, VE);</li>\n      <li>Eumovate Cream (AU, NZ);</li>\n      <li>Ezex (BD);</li>\n      <li>Flixoderm Eczema &amp; Dermatitis Cream (NZ);</li>\n      <li>Miclo (BD);</li>\n      <li>Rettavate (GR);</li>\n      <li>Solderma (IT);</li>\n      <li>Sterisone (LK);</li>\n      <li>U-Closone (ET, MY, TH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    B&ouml;ckle BC, Jara D, Nindl W, Aberer W, Sepp NT. Adrenal insufficiency as a result of long-term misuse of topical corticosteroids. <i>Dermatology</i>. 2014;228(4):289-293.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clobetasone-united-states-not-available-drug-information/abstract-text/24751677/pubmed\" target=\"_blank\" id=\"24751677\">24751677</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dhar S, Seth J, Parikh D. Systemic side-effects of topical corticosteroids. <i>Indian J Dermatol</i>. 2014;59(5):460-464.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clobetasone-united-states-not-available-drug-information/abstract-text/25284850/pubmed\" target=\"_blank\" id=\"25284850\">25284850</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Halverstam CP, Vachharajani A, Mallory SB. Cushing syndrome from percutaneous absorption of 1% hydrocortisone ointment in Netherton syndrome. <i>Pediatr Dermatol</i>. 2007;24(1):42-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clobetasone-united-states-not-available-drug-information/abstract-text/17300648/pubmed\" target=\"_blank\" id=\"17300648\">17300648</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids.<i> J Am Acad Dermatol</i>. 2006;54(1):1-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clobetasone-united-states-not-available-drug-information/abstract-text/16384751/pubmed\" target=\"_blank\" id=\"16384751\">16384751</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hosking GP, Elliston H. Benign intracranial hypertension in a child with eczema treated with topical steroids. <i>Br Med J</i>. 1978;1(6112):550-551.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clobetasone-united-states-not-available-drug-information/abstract-text/630215/pubmed\" target=\"_blank\" id=\"630215\">630215</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koutroulis I, Papoutsis J, and Kroumpouzos G. Atopic dermatitis in pregnancy: current status and challenges. <i>Obstet Gynecol Surv</i>. 2011;66(10):654-663.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clobetasone-united-states-not-available-drug-information/abstract-text/22112526/pubmed\" target=\"_blank\" id=\"22112526\">22112526</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kristmundsdottir F, David TJ. Growth impairment in children with atopic eczema. <i>J R Soc Med</i>. 1987;80(1):9-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clobetasone-united-states-not-available-drug-information/abstract-text/3560137/pubmed\" target=\"_blank\" id=\"3560137\">3560137</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leachman SA and Reed BR. The use of dermatologic drugs in pregnancy and lactation. <i> Dermatol Clin</i>. 2006;24(2):167-197, vi.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clobetasone-united-states-not-available-drug-information/abstract-text/16677965/pubmed\" target=\"_blank\" id=\"16677965\">16677965</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Spectro EczemaCare Medicated Cream (clobetasone) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Consumer Healthcare Inc; October 2012.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 107874 Version 14.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F46443940\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F46443942\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F46447011\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F46447012\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F46447013\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F46447015\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F46447016\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F46443941\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F46447021\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F46447020\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F46447017\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F46446873\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F46731052\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F46447005\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F46447006\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F46221694\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F46221691\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F46446874\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F46446886\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F46447019\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F46447009\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F46507009\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/107874|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=clobetasone-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">Clobetasone (United States: Not available): Patient drug information</a></li></ul></div></div>","javascript":null}